Hitting the Target in HER2-Positive Metastatic Colorectal Cancer
STATEMENT OF NEED
An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatment... |
|
Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC
In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!
STATEMENT OF NEED
Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite... |
|
Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs
STATEMENT OF NEED
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ... |
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Parkinson’s Disease " Updates in Diagnosis and Patient Management
Parkinson's disease is a neurodegenerative disorder, second only in prevalence to Alzheimer’s disease. Numerous therapeutic options, including carbidopa/levodopa, monoamine oxidase-B inhibitors, dopamine agonists, and device-assisted therapies, are available for treatment. These treatments are indicated at different stages following diagnosis. However, Parkinson’s disease progresses at highly variable rates, and no biomarkers, laboratory tests, or gold standard indexes are available t... |
|
Reducing Risks in Asthma: Mucus Plugs and Airway Obstruction
Target Audience
The educational design of this activity addresses the needs of pulmonology and clinical immunology clinicians who manage patients with severe asthma who are at risk for mucus plugs.
Program Overview
This Point-of-Care 201 program has been designed to educate and promote critical thinking through a discussion-based format that is accompanied by 3-dimensional animation. Expert faculty examine various sides of key clinical issues in asthma"including exploration of the pa... |
|
Applying Guidelines and Latest Evidence to the Management of Moderate‐to‐Severe Asthma in Children and Adults
Target Audience
The educational design of this activity addresses the needs of pulmonologists, allergists/immunologists, NPs and PAs, and other clinicians involved in the management of patients with moderate‐to‐severe asthma.
Program Overview
Patients with asthma and underlying comorbidities require personalized treatment to achieve asthma control. Children with asthma have an especially high burden of symptoms, and are at risk of impaired lung development if asthma control cannot be ... |
|
Update in Clinical Cardiology - LIVE STREAMING or IN PERSON
The Comprehensive Clinical Cardiology Update
Evaluation • Treatment • Patient Care • Procedures • Challenging Cases
Update in Clinical Cardiology will be held on October 16 " 18, 2024. You have the option to attend either online as the course is live streamed or in person in Boston, MA.
OVERVIEW
This course provides comprehensive updates for state-of-the-art care and guidance to incorporate them into daily practice to optimize patient outcomes.
Coverage includes:
• ... |
|
Improving Alzheimer’s Disease Management: Updates on Patient Diagnosis and Treatment
The face of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) diagnosis and management is rapidly changing. A growing understanding of AD pathophysiology has shaped research of targeted therapies and helped clinicians better understand the causes of the disease and the utility of biomarkers. Though cognitive testing is still a critical component of diagnosis, it no longer stands alone. Biomarkers are increasingly incorporated into practice to aid in diagnosis of MCI and AD and to ... |
|
Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies Into Care for Patients With Relapsed/Refractory Multiple Myeloma
As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, several factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administ... |
|
Top 10 Questions on Biomarkers in Early Alzheimer’s Disease: Improving Diagnosis and Use of Targeted Therapies
The past several years have seen numerous advances in Alzheimer’s disease (AD) diagnosis and management. Most recently, approval of antiamyloid monoclonal antibodies has revolutionized AD management and has required that patients have amyloid burden verified prior to initiating treatment. Biomarkers, whether obtained from cerebrospinal fluid (CSF) or positron emission tomography (PET) scans, are critical to the early diagnosis of AD and its subsequent management. Plasma biomarkers are an eme... |
|
Alzheimer’s Disease & Dementia: A Practical Guide
Alzheimer’s Disease and Dementia: A Practical Guide is a 3-hour online continuing education (CE) course that offers healthcare professionals a basic foundation in Alzheimer's disease prevention, diagnosis, and risk management through a literature review of evidence-based information and best practices.
Practical information to aid healthcare professionals as they interact with clients who are diagnosed with any of the many types of dementia is presented. For the purposes of this cour... |